DESIGN: Nucleoside reverse transcriptase inhibitors (NRTIs) exhibit mitochondrial toxicity. The mitochondrial deoxynucleotide carrier (DNC) transports nucleotide precursors (or phosphorylated NRTIs) into mitochondria for mitochondrial (mt)DNA replication or inhibition of mtDNA replication by NRTIs. Transgenic mice (TG) expressing human DNC targeted to murine myocardium served to define mitochondrial events from NRTIs in vivo and findings were corroborated by biochemical events in vitro. METHODS: Zidovudine (3'-azido-2',3'-deoxythymidine; ZDV), stavudine (2', 3'-didehydro-2', 3'-deoxythymidine; d4T), or lamivudine ((-)-2'-deoxy-3'-thiacytidine; 3TC) were administered individually to TGs and wild-type (WT) littermates (35 days) at human doses with drug-free vehicle as control. Left ventricle (LV) mass was defined echocardiographically, mitochondrial ultrastructural defects were identified by electron microscopy, the abundance of cardiac mtDNA was quantified by real time polymerase chain reaction, and mtDNA-encoded polypeptides were quantified. RESULTS: Untreated TGs exhibited normal LV mass with minor mitochondrial damage. NRTI monotherapy (either d4T or ZDV) increased LV mass in TGs and caused significant mitochondrial destruction. Cardiac mtDNA was depleted in ZDV and d4T-treated TG hearts and mtDNA-encoded polypeptides decreased. Changes were absent in 3TC-treated cohorts. In supportive structural observations from molecular modeling, ZDV demonstrated close contacts with K947 and Y951 in the DNA pol gamma active site that were absent in the HIV reverse transcriptase active site. CONCLUSIONS: NRTIs deplete mtDNA and polypeptides, cause mitochondrial structural and functional defects in vivo, follow inhibition kinetics with DNA pol gamma in vitro, and are corroborated by molecular models. Disrupted pools of nucleotide precursors and inhibition of DNA pol gamma by specific NRTIs are mechanistically important in mitochondrial toxicity.
DESIGN: Nucleoside reverse transcriptase inhibitors (NRTIs) exhibit mitochondrial toxicity. The mitochondrial deoxynucleotide carrier (DNC) transports nucleotide precursors (or phosphorylated NRTIs) into mitochondria for mitochondrial (mt)DNA replication or inhibition of mtDNA replication by NRTIs. Transgenic mice (TG) expressing humanDNC targeted to murine myocardium served to define mitochondrial events from NRTIs in vivo and findings were corroborated by biochemical events in vitro. METHODS: Zidovudine (3'-azido-2',3'-deoxythymidine; ZDV), stavudine (2', 3'-didehydro-2', 3'-deoxythymidine; d4T), or lamivudine ((-)-2'-deoxy-3'-thiacytidine; 3TC) were administered individually to TGs and wild-type (WT) littermates (35 days) at human doses with drug-free vehicle as control. Left ventricle (LV) mass was defined echocardiographically, mitochondrial ultrastructural defects were identified by electron microscopy, the abundance of cardiac mtDNA was quantified by real time polymerase chain reaction, and mtDNA-encoded polypeptides were quantified. RESULTS: Untreated TGs exhibited normal LV mass with minor mitochondrial damage. NRTI monotherapy (either d4T or ZDV) increased LV mass in TGs and caused significant mitochondrial destruction. Cardiac mtDNA was depleted in ZDV and d4T-treated TG hearts and mtDNA-encoded polypeptides decreased. Changes were absent in 3TC-treated cohorts. In supportive structural observations from molecular modeling, ZDV demonstrated close contacts with K947 and Y951 in the DNA pol gamma active site that were absent in the HIV reverse transcriptase active site. CONCLUSIONS: NRTIs deplete mtDNA and polypeptides, cause mitochondrial structural and functional defects in vivo, follow inhibition kinetics with DNA pol gamma in vitro, and are corroborated by molecular models. Disrupted pools of nucleotide precursors and inhibition of DNA pol gamma by specific NRTIs are mechanistically important in mitochondrial toxicity.
Authors: Leonard W Velsor; Miro Kovacevic; Mark Goldstein; Heather M Leitner; William Lewis; Brian J Day Journal: Toxicol Appl Pharmacol Date: 2004-08-15 Impact factor: 4.219
Authors: R Carrozzo; B Bornstein; S Lucioli; Y Campos; P de la Pena; N Petit; C Dionisi-Vici; L Vilarinho; T Rizza; E Bertini; R Garesse; F M Santorelli; J Arenas Journal: Hum Mutat Date: 2003-04 Impact factor: 4.878
Authors: Marilyn J Crain; Miriam C Chernoff; James M Oleske; Susan B Brogly; Kathleen M Malee; Peggy R Borum; William A Meyer; Wendy G Mitchell; John H Moye; Heather M Ford-Chatterton; Russell B Van Dyke; George R Seage Iii Journal: J Infect Dis Date: 2010-07-15 Impact factor: 5.226
Authors: William Lewis; Brian J Day; James J Kohler; Seyed H Hosseini; Sherine S L Chan; Elgin C Green; Chad P Haase; Erin S Keebaugh; Robert Long; Tomika Ludaway; Rodney Russ; Jeffrey Steltzer; Nina Tioleco; Robert Santoianni; William C Copeland Journal: Lab Invest Date: 2006-02-19 Impact factor: 5.662
Authors: Todd Hulgan; Richard Haubrich; Sharon A Riddler; Pablo Tebas; Marylyn D Ritchie; Grace A McComsey; David W Haas; Jeffrey A Canter Journal: AIDS Date: 2011-01-02 Impact factor: 4.177
Authors: Amy Fleischman; Stine Johnsen; David M Systrom; Mirko Hrovat; Christian T Farrar; Walter Frontera; Kathleen Fitch; Bijoy J Thomas; Martin Torriani; Hélène C F Côté; Steven K Grinspoon Journal: Am J Physiol Endocrinol Metab Date: 2007-02-06 Impact factor: 4.310
Authors: Emilio L Streck; Giselli Scaini; Gislaine T Rezin; Jeverson Moreira; Celine M Fochesato; Pedro R T Romão Journal: Metab Brain Dis Date: 2008-09-24 Impact factor: 3.584
Authors: Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Judith S Currier; Jens D Lundgren; Michael P Dubé; Steven E Lipshultz; Priscilla Y Hsue; Kathleen Squires; Morris Schambelan; Peter W F Wilson; Kevin E Yarasheski; Colleen M Hadigan; James H Stein; Robert H Eckel Journal: Circulation Date: 2008-06-19 Impact factor: 29.690
Authors: James Corey Adams; Michael J Keiser; Li Basuino; Henry F Chambers; Deok-Sun Lee; Olaf G Wiest; Patricia C Babbitt Journal: PLoS Comput Biol Date: 2009-08-21 Impact factor: 4.475
Authors: Iwen F Grigsby; Lan Pham; Louis M Mansky; Raj Gopalakrishnan; Kim C Mansky Journal: Ther Clin Risk Manag Date: 2010-02-02 Impact factor: 2.423